Dr. Lu [Jake Wetchler Foundation Fellow for Pediatric Innovation] aims to develop antibody-drug conjugates (ADCs) that can specifically recognize and kill acute myeloid leukemia (AML) cancer cells. His goal is to generate highly specific ADCs that will attack tumor cells without having harmful effects on normal cells. This work may identify new clinical candidate drugs with optimized efficacy.

 

---

Project Title: "Homogeneous antibody-drug conjugates containing unnatural amino acid for targeted AML therapy"

Institution: The Scripps Research Institute

Sponsor(s) / Mentor(s): Peter G. Schultz, PhD

Cancer Type: Leukemias

Research Area: Biomedical Engineering